摘要
目的分析卵巢癌患者外周血T淋巴细胞亚群、免疫球蛋白的变化,监测卵巢癌患者的免疫功能水平。方法用流式细胞仪测定45例卵巢癌患者、35例卵巢良性肿瘤患者和30名健康对照组的外周血T淋巴细胞亚群,采用免疫比浊法测定3组样本血清Ig A、Ig G、Ig M含量。结果卵巢癌患者全血CD8+明显高于健康对照组(P<0.05),而血CD4+及CD4+/CD8+比值则显著低于健康对照组(P<0.05)。Ig G、Ig M水平均高于对照组(P<0.05),而Ig A水平两组无显著差异(P>0.05)。外周血T淋巴细胞亚群和免疫球蛋白的改变与卵巢癌病理分期有关,分期越晚,CD4+及CD4+/CD8+比值越低,CD8+、Ig G、Ig M水平越高,Ⅱ期与Ⅲ期、Ⅳ期之间有显著性差异(P<0.05)。结论卵巢癌患者细胞免疫功能降低,体液免疫功能增强。外周血T细胞亚群和免疫球蛋白的检测对判断卵巢癌患者的病情、预后以及机体的免疫功能的判断有一定意义。
Objective To evaluate the alternation of peripheral blood T-lymphocyte cell subsets and immunoglobulin and investigate the diagnostic value of them in patients with ovarian cancer. Methods Peripheral blood samples were collected from the 45 ovarian cancer,30 healthy people and 35 benign ovarian disease patients,the level of T-Lymphocyte subsets were detected by Beckman Coulter-EPICS-XL Flow Cytometry( FCM),and the level of Ig A,Ig G and Ig M were detected by the immunoturbidimetric assay. Results The percentages of T-lymphocyte subsets CD8+in ovarian cancer patients were higher than those in control groups( P 〈 0. 05). The percentages of T-lymphocyte subsets CD4+and the ratio of CD4+/ CD8+in ovarian cancer patients were significantly lower than those in control groups( P 〈 0. 05). The concentrations of Ig G and Ig M in ovarian cancer groups were higher than those in control( P 〈 0. 05). The concentrations of Ig A were not significantly different between those groups( P 〉 0. 05). The changes of peripheral blood T lymphocyte subsets and immunoglobulin of ovarian cancers were related to pathological stages. The more later of pathological stage,the lower of CD4 + and CD4 + / CD8 + ratio,and the more higher of CD8 +,Ig G and Ig M level. There was significantly difference between stage Ⅱwith stage Ⅲ and IV( P 〈 0. 05). Conclusion The cellular immunity function of ovarian cancer patients is decreased,and humeral immunoreactions are increased. Determination of peripheral blood T cell subsets and immunoglobulin in patients with ovarian cancer might be of some significance in the diagnosis of the state of the ovarian cancers,evaluation the prognosis and the state of immunity in organism.
出处
《标记免疫分析与临床》
CAS
2016年第2期174-176,共3页
Labeled Immunoassays and Clinical Medicine